BioLegend

From Wikipedia, the free encyclopedia
Jump to: navigation, search
BioLegend
Industry Biotechnology
Founded 2002
Headquarters San Diego, California, U.S.
Area served
Worldwide
Key people
Gene Lay, D.V.M., Founder and CEO
Products Antibodies, ELISA Kits and Sets, Recombinant Proteins, Custom Assay Development, Buffers and Solutions
Website http://www.biolegend.com/


BioLegend is a global developer and manufacturer of antibodies and reagents used in biomedical research located in San Diego, California.[1] It was incorporated in June 2002 and has since expanded to include BioLegend Japan KK, where it is partnered with Tomy Digital Biology Co., Ltd. in Tokyo, BioLegend Europe in the United Kingdom, BioLegend GmbH in Germany, and BioLegend UK Ltd in the United Kingdom. BioLegend manufactures products in the areas of neuroscience, cell immunophenotyping, cytokines and chemokines, adhesion, cancer research, T regulatory cells, stem cells, innate immunity, cell-cycle analysis, apoptosis, and modification-specific antibodies. Reagents are created for use in flow cytometry, ELISA, immunoprecipitation, Western blotting, immunofluorescence microscopy, immunohistochemistry, and in vitro or in vivo functional assays.[2]

History[edit]

BioLegend was founded by CEO, Gene Lay, D.V.M., who was also the co-founder of PharMingen. In 2011, BioLegend co-developed and introduced Brilliant Violet(TM)-conjugated antibodies, using a novel fluorophore based on Nobel Prize-winning chemistry developed by Sirigen.[3]

References[edit]

  1. ^ "Archived copy". Archived from the original on 2011-07-18. Retrieved 2009-07-21. 
  2. ^ "Archived copy". Archived from the original on 2012-03-13. Retrieved 2009-07-21. 
  3. ^ http://www.biolegend.com/company/